The paper identifies combinatorial KRAS/FGFR dependence in pancreatic cancer through genetic interaction mapping and shows that combined inhibition overcomes resistance.

bioRxiv · Sep 25, 2026 · PreprintCancer Biology

Generation of a biliary tract cancer cell line atlas reveals molecular subtypes and therapeutic targets

Vindhya Vijay, Negin Karisani, Lei Shi, Yu-Han Hung, Phuong Vu, Prabhat Kattel, Lauren Kenney, Joshua Merritt, Ramzi Adil, Qibiao Wu, Yuanli Zhen, Robert Tyler Morris, Johannes Kreuzer, Meena Kathiresan, Xcanda Ixchel Herrera Lopez, , Nabeel M. Bardeesy

This study creates a biliary tract cancer cell line atlas using multi-omics data to identify molecular subtypes and therapeutic targets.

Cancer Discovery · May 12, 2025Peer-reviewedCancer Biology

Identification of potent biparatopic antibodies targeting FGFR2 fusion driven cholangiocarcinoma.

Saireudee Chaturantabut, Sydney Oliver, Dennie Tompers Frederick, Jiwan Kim, Foxy P. Robinson, Alessandro Sinopoli, Tianyu Song, Yao He, Y.H. Chang, Diego J. Rodriguez, Liang Chang, Devishi Kesar, Meilani Ching, Ruvimbo Dzvurumi, Adel Atari, , William R. Sellers

The paper identifies biparatopic antibodies targeting FGFR2 extracellular domain that effectively block FGFR2 fusion-driven cholangiocarcinoma signaling and growth.

Journal of Clinical Investigation · Feb 27, 2025Peer-reviewedCancer Biology

A Kinetic Scout Approach Accelerates Targeted Protein Degrader Development

Angela T. Fan, Gillian E. Gadbois, Hai‐Tsang Huang, Charu Chaudhry, Jiewei Jiang, Logan H. Sigua, Emily R. Smith, Sitong Wu, Grace J. Poirier, Kara Dunne-Dombrink, Pavitra Goyal, Andrew J. Tao, William R. Sellers, Eric S. Fischer, Katherine A. Donovan, Fleur M. Ferguson

This study develops a kinetic scout approach to accelerate targeted protein degrader development by tuning ligand residence time through chemical proteomics and mechanistic assays.

Angewandte Chemie International Edition · Nov 27, 2024Peer-reviewedPharmacology & Toxicology